{
  "ticker": "BOT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967023",
  "id": "02967023",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250708",
  "time": "0827",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250708/pdf/06lkx61d71dvjg.pdf",
  "summary": "### **Botanix Pharmaceuticals - Sofdra\u2122 Launch Update (8 July 2025)**  \n\n**Material Highlights:**  \n- **Gross sales:** ~$25M AUD (Jan\u2013Jun 2025), with monthly growth.  \n- **Prescriptions:** 16,000+ filled (6,700+ patients) since launch.  \n- **Prescriber uptake:** 2,300+ unique prescribers in June 2025.  \n- **Refill rates:** 3.4 fills/patient (vs. industry avg. of 2), with 95% adherence in auto-refill program.  \n- **Gross-to-Net (GTN) yield:** 23% (targeting 30\u201340% range).  \n- **Commercial expansion:** Sales force scaling to 50 territories by Q2 FY2026.  \n\n**No material capital markets actions (e.g., raising, guidance change) identified.**  \n\n*(Note: Omitted operational/forward-looking commentary as non-material for trading decisions.)*",
  "usage": {
    "prompt_tokens": 2437,
    "completion_tokens": 211,
    "total_tokens": 2648,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-07T22:52:33.640616"
}